| Similar Articles |
|---|
 |
The Motley Fool
October 20, 2005
Stephen D. Simpson |
Wide Eyes at Alcon Excellent margin performance fueled exceptional growth for this eye-care titan. This is a strong and valuable cash-producing franchise, and it deserves a premium valuation -- but how much of a premium?   |
The Motley Fool
May 1, 2006
Stephen D. Simpson |
Alcon Still Not Living Up to Valuation Though this is a very solid medical technology company, its valuation still looks too high. |
The Motley Fool
July 25, 2006
Stephen D. Simpson |
An Eye-Opening Quarter at Alcon Good news may have been overdue from the eye-care company, but the jubilation seems overdone. Investors, take note. |
The Motley Fool
August 7, 2006
Stephen D. Simpson |
Advanced Medical Optics Still a Little Bloodshot This eye-care stock has done relatively well despite some ongoing sales issues. |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Cooper's Bleary Performance Missteps in strategy and operations for the contact lens company are coming home to roost. As is almost always the case with turnarounds, this is an idea with above-average risk, so don't make the mistake of underestimating the odds that things could get even worse. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Do The Eyes Have It for Bausch & Lomb? New product launches and extensions coupled with improving margins should boost results. Investors, take note. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
Can ESRX Spell P-r-o-f-i-t-s? A company focused on lowering medical costs sounds like a good idea, but investors should dig deeper. While pharmaceutical benefits manager Express Scripts offers high growth and high valuation, it may also offer higher-than-average risk. |
The Motley Fool
September 10, 2007
Lawrence A. Rothman |
Cooper Needs a Clearer Vision Earnings reports from vision-correction specialist Cooper show that revenue did rise, but gross margins decreased, and management lowered guidance significantly. |
The Motley Fool
July 21, 2006
Stephen D. Simpson |
Lilly Wilts Neither the valuation nor the pipeline of this pharma makes for a compelling investment case. |
The Motley Fool
October 27, 2005
Brian Gorman |
Bausch & Lomb's Cloudy Quarter An accounting scandal at a Brazilian subsidiary clouded third-quarter results, but the underlying business still looks good. Investors, take note. |
The Motley Fool
February 11, 2005
Stephen D. Simpson |
For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant. |
The Motley Fool
April 22, 2004
Brian Gorman |
Bausch & Lomb Delivers The 150-year-old eye-care company's sales aren't sizzling, but its profitability is improving. |
The Motley Fool
February 10, 2006
Stephen D. Simpson |
UTStarcom Still a Mess A contract revenue recognition problem serves as a reminder of the management quality issues here. Valuation is enticingly low, and simply a mediocre performance from management should be enough to make this company profitable. |
The Motley Fool
April 24, 2006
Stephen D. Simpson |
Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions. |
The Motley Fool
May 31, 2007
Billy Fisher |
Not Seeing 20/20 at Advanced Medical Optics The company recalls a contact lens solution that might be linked to a rare infection. Investors, take note. |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
The Motley Fool
February 21, 2006
Stephen D. Simpson |
A Little Sand in the EYE Advanced Medical Optics' transition effort looks messy, but should pay off later this year. Investors need to monitor a few key issues here, though. |
The Motley Fool
November 2, 2005
Stephen D. Simpson |
AMO Focuses on the Giants Advanced Medical Optics sets its sights on the big players in eye care. Will David be able to take on the Goliaths? Investors, take note. |
The Motley Fool
March 3, 2009
Brian Orelli |
Pfizer Eyes Generic Growth Two partnerships in one day? Oh my! |
The Motley Fool
December 13, 2005
Stephen D. Simpson |
Take a Good, Long Look at Cooper Tough competition is eating away at the contact lens maker's growth. This is a stock that could require an above-average level of patience and tolerance for risk in the meantime. |
The Motley Fool
July 5, 2005
Brian Gorman |
Bausch & Lomb Eyes China The firm's latest purchase will add geographic diversity to its pharmaceutical business. Investors, take note. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now. |
InternetNews
September 9, 2005
Paul Shread |
Stocks Rise, Intel Falls Stocks posted strong gains Friday... Shares of Intel fell 3%... Texas Instruments ended the day unchanged... etc. |
InternetNews
October 17, 2005
Paul Shread |
Big Blue Shows Investors the Green IBM posted quarterly that were well above Wall Street expectations... Novellus missed earnings estimates... Stocks rose... Nortel climbed... etc. |
The Motley Fool
August 10, 2010
Seth Jayson |
Marginal Performance at Alcon The more Alcon keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. |
The Motley Fool
December 15, 2006
Tom Taulli |
Guidance Software: A Lawsuit's Best Friend This software company has found a strong growth channel. While Guidance is definitely solid, it may be worth waiting for the valuation to settle down. |
BusinessWeek
January 7, 2010
Capell & Doherty |
What Novartis Sees in Eye Care Novartis CEO Dan Vasella's $50 billion bet on Alcon could help insulate it from the vagaries of the drug business. |
The Motley Fool
July 22, 2004
Nathan Slaughter |
VISX Eyes Future The vision-correction firm posts triple-digit earnings growth, capturing the attention of investors. |
The Motley Fool
April 11, 2006
Rick Aristotle Munarriz |
Bausch & Lomb Sees Eye to Ay The contact lens specialist gets tripped up over its potentially infected ReNu brand. Bausch & Lomb's stock took a 9% hit in after-hours trading on the news. |
The Motley Fool
April 8, 2008
Brian Lawler |
Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history. |
The Motley Fool
August 24, 2010
David Meier |
Could Alcon Be a Multibagger? Strong returns on equity can generate powerful shareholder returns. |
The Motley Fool
April 22, 2008
Brian Lawler |
No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year. |
The Motley Fool
January 4, 2010
Brian Orelli |
You Don't Need Your Contacts In to See This Deal Novartis acts first to grab the rest of Nestle's stake in Alcon. |
The Motley Fool
July 16, 2010
Brian Orelli |
A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year. |
The Motley Fool
June 5, 2008
Brian Lawler |
Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth. |
The Motley Fool
January 29, 2009
Brian Orelli |
Novartis: Diversification Isn't Good Enough Novartis has become a better diversified company, with acquisitions of vaccines specialist Chiron and 25% of eye-care specialist Alcon, but it's far from a cure all, as the fourth quarter showed. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time. |
The Motley Fool
August 5, 2010
Seth Jayson |
Show Me the Money, Alcon With questionable cash sources comprising 4% of the cash flow from operations for Alcon, I am pretty confident things are OK. |
The Motley Fool
January 27, 2010
Brian Orelli |
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note. |
